Treace Medical Concepts Takes Center Stage at Major Investor Conferences
PONTE VEDRA, Fla. — Treace Medical Concepts, Inc. (NASDAQ: TMCI), a pioneering company in the medical technology sector, is excited to unveil its participation in two prominent upcoming investor conferences aimed at sharing its innovative approach to surgical treatments for bunions and midfoot deformities.
Event Details of Interest
On the horizon, Treace will be engaging with investors at the:
UBS Global Healthcare Conference
Scheduled for November 10, attendees can expect a lively fireside chat commencing at 11:45 AM ET, where key representatives from Treace will discuss the company’s growth and innovative solutions.
Stifel 2025 Healthcare Conference
Following this, Treace will make its presence felt at the Stifel 2025 Healthcare Conference on November 11, creating opportunities to deepen investor relations and provide an insight into their cutting-edge operations.
Access to Webcast and Investor Resources
For those unable to attend, Treace offers a live webcast and subsequent playback of the fireside chat on its dedicated investor relations website. This platform serves as a valuable resource for stakeholders looking to stay informed about the company’s latest updates and initiatives.
About Treace Medical Concepts
At the heart of Treace Medical Concepts is a commitment to revolutionizing the treatment of bunions. With about 65 million Americans residing with this complex 3-dimensional deformity, Treace focuses on enhancing the quality of care available to surgical candidates. The company estimates that approximately 1.1 million individuals each year are potential candidates for bunion surgery.
One of the notable advancements from Treace is the Lapiplasty 3D Bunion Correction System. This system employs a sophisticated blend of instruments, implants, and surgical techniques designed to address the core issues related to bunion deformities, ultimately allowing patients to return to their active lifestyles quickly.
Innovative Solutions for Bunion Treatment
Not stopping there, Treace also introduced the Adductoplasty Midfoot Correction System, aimed at ensuring reproducible corrections for various midfoot deformities. In addition, the company has rolled out the SpeedMTP™ Rapid Compression Implant, which focuses on the fusion of big toe joints, as well as two specialized systems for minimally invasive procedures: the Nanoplasty™ and Percuplasty™ systems.
Moreover, Treace is steadily expanding its reach within the foot and ankle market with the SpeedPlate® Rapid Compression Implants, encouraging broader surgical versatility within its range of procedures.
Staying Connected
Investors and interested parties are encouraged to explore Treace’s online platforms. Connections can be formed through various social media channels like LinkedIn, X (formerly Twitter), Facebook, and Instagram, where Treace engages with its community and shares timely updates.
Contact Information for Further Engagement
For any inquiries, Treace Medical Concepts can be contacted directly:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
Frequently Asked Questions
What is the main focus of Treace Medical Concepts?
Treace focuses on innovative medical technologies for the surgical management of bunions and related midfoot deformities.
When is Treace participating in the upcoming conferences?
Treace will participate in the UBS Global Healthcare Conference on November 10 and the Stifel 2025 Healthcare Conference on November 11.
Where can I find more information about Treace's events?
Details about Treace's events can be found on their investor relations website, which hosts information relevant to investors.
How has Treace changed bunion surgery?
Treace has developed the Lapiplasty 3D system to address all dimensions of bunion deformities, enhancing recovery times and surgical outcomes.
Whom should investors contact for more information?
Investors can reach out to Mark L. Hair, the CFO of Treace, or connect with Philip Trip Taylor from the Gilmartin Group for inquiries.
